The synergistic actions of glucagon to reduce food intake and increase energy expenditure, GLP‐1 to reduce calorie intake, and GIP to potentiate bodyweight loss may aid in the treatment of obesity (Figure 2). The gene discussed is GIP; the disease is obesity due to melanocortin 4 receptor deficiency.